Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review

Table 6

Characteristics of JAK inhibitor treatment.

Patient	Gender	Age	Ocular inflammation	Inhibitor	Dosage	Treatment duration	Combined therapy	Side effects	Systematic symptoms	Ocular symptoms
1	Female	59	Keratitis	Tofacitinib	5 mg bid	1 month; Improved after 2 weeks	NA	No	Inactive	Inactive
2	Female	45	Anterior and intermediate uveitis	Tofacitinib	11 mg daily	4months; Improved after 1 month	MTX	No	Combination: Inactive; Monotherapy: Active	Inactive
3	Female	40	Scleritis	Tofacitinib	11 mg daily	9 months; Improved after 1 week	MTX	No	No systematic symptoms	Inactive
4	Female	22	Anterior uveitis	Tofacitinib	5 mg bid	9 months	MTX; 2.5 mg qod	No	NA	Inactive
5	Female	45	Scleritis	Tofacitinib	5 mg bid	6 months	Prednisone; 5 mg qd	No	NA	Inactive
6	Female	43	Panuveitis	Tofacitinib	5 mg bid	7 months	NA	No	Inactive	Inactive
7	Female	18	Panuveitis	Baricitinib	4 mg; Qd	5 months	MTX; 15 mg qw; Prednisone; 12.5 mg qd	No	Active	Inactive
8	Female	37	Anterior uveitis	Baricitinib	4 mg qd	13 months	NA	No	Inactive	Active
9	Male	21	Panuveitis	Baricitinib	4 mg qd	4 months	MTX; 15 mg qw; Prednisone; 7.5 mg qd	No	Active	Inactive
10	Male	65	Scleritis	Tofacitinib	5 mg bid	Improvd after 1 month	MMF 500 mg bid; Prednisone 2.5 mg qod	No	No systematic symptoms	Inactive
11	Male	43	Conjunctivitis	Baricitinib	4 mg qd	6month; Improvd after 2 weeks	MTX; 25 mg qw; Prednisolone; 6 mg qd	Yes	NA	Inactive

Note: NA: not available.